Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Blue Sky Uranium Expands Drill Plan to Advance the Ivana Uranium-Vanadium Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Healthcare Biotechnology
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022

Business Wire April 20, 2022

Harrow Health Announces Appointments to Its Board of Directors

Business Wire March 31, 2022

Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results

Business Wire March 10, 2022

Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer

Business Wire March 10, 2022

Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022

Business Wire February 24, 2022

Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100

Business Wire February 22, 2022

Harrow Health to Present at Aegis Virtual Conference

Business Wire February 15, 2022

Harrow Health Publishes Corporate Transparency Report

Business Wire February 8, 2022

Harrow Health to Participate in H.C. Wainwright BioConnect Conference

Business Wire January 10, 2022

Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA

Business Wire January 4, 2022

Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops

Business Wire December 20, 2021

Harrow Health Added to the Nasdaq Biotechnology Index

Business Wire December 13, 2021

EyePoint Pharmaceuticals and Harrow Health's ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®

GlobeNewswire December 7, 2021

Harrow Health Announces Third Quarter 2021 Financial Results

Business Wire November 9, 2021

Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021

Business Wire October 25, 2021

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

Business Wire September 2, 2021

Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.

Business Wire August 18, 2021

Harrow Health to Participate in Two Upcoming Virtual Investor Conferences

Business Wire August 12, 2021

Harrow Health Announces Second Quarter 2021 Financial Results

Business Wire August 10, 2021

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

Business Wire July 27, 2021